InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 149487

Monday, 11/25/2013 7:35:40 PM

Monday, November 25, 2013 7:35:40 PM

Post# of 345950
Google to 23andme to Calico + Peregrine ... is Peregrine that bridge that assists both sides ?

Sept 5, 2013

Health issues are an area of personal interest for Google co-founders Page and Sergey Brin. In May, Page announced that he had a rare nerve disease that limited the movement of his vocal cords and briefly sidelined him from public speaking. He also said he had been diagnosed with Hashimoto's thyroiditis, a thyroid inflammatory condition he said gives him no trouble.

Brin has said that he has a higher-than-average chance of being diagnosed with Parkinson's disease, which his mother had. He believes he can lower his chances of getting Parkinson's from 50 percent to 13 percent through a strict regimen of diet and physical exercise.

Brin learned of his increased chance of Parkinson's through tests he took with 23andMe, a biotech firm founded by his wife, in which Google has invested.

Google previously tried to get involved in the healthcare business with limited success. Google Health, which provided consumers with a way to store their medical records online, was shuttered in 2011 after three years. Page said at the time that the service had failed to catch on with the general public.

http://www.reuters.com/article/2013/09/18/us-google-calico-idUSBRE98H0R720130918



Google obviously has the money to take the risk to venture deep into the Healthcare industry and now, 23andme is running into FDA trouble. Its clearly noted that the FDA didn't take much notice back in 2007 but starting in 2010 maybe they (lobbyists) were put in play to make sure Google advance too much in this field.

FDA halts sales of 23andMe DNA test kits

Nov 25, 2013


23andMe's saliva-based test kit, launched more than 5 years ago, claims to tell customers if they are at risk for more than 250 diseases and health conditions. The FDA says only medical tests that have been cleared by the government are permitted to make such claims.

For years, 23andMe resisted government regulation, arguing that it simply provides consumers with information, not a medical service. But last year the company changed course, submitting several of the disease-specific tests included in its test kit.

Company executives previously said that they first contacted the FDA in 2007, before launching their product. The agency did not take an interest in the technology until 2010, when it issued letters to several testing companies, warning that their products must be approved as safe and effective.

http://www.usatoday.com/story/news/nation/2013/11/25/23andme/3699329/


---------------------------------------------------------------

So Google must shake it off and continue its course so they then start Calico and many of the Sr. Execs at Google have that desire to attempt that which is almost impossible- attempt the Health Venture path and now, they hire the best out of Genentech and maybe... just maybe -- make some deal with Peregrine?

K&L Gates in play with Peregrine
Dr. Robert Garnick - ex-Genentech
Googles "Calico" with all the ex-Genentech players

I say this: If Peregrine came out and stated they are now being backed by the likes of "Calico" with $2 Billion in cash payable in quarterly payments of $250M each for a 40% stake in Peregrine would close this deal down and fast.

I know its much more complicated with all the details and what Peregrine ultimately needs is a Big Pharma built-in "infrastructure" ? right..? Well $2 Billion is a start to initiate the "buy that BP infrastructure in pieces" pretty quickly with all the collaboration deals going on right now.

It doesn't matter what someone pays for the first half of Peregrine... its the 2nd half that matters for the buyout (see Genentech) but Peregrine shouldn't worry too much about that now and neither would Calico.

This would place PPHM above $5+ overnight and not look back. Peregrine can then sell 10Million shares at $20 for the vaults to never touch and always hold $200Million in cash on hand.

Peregrine would never be under a sub $5 stock again and Institutions would be buying in big time.

Get this train moving

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News